Pediatrix Medical Group MD Malpractice Loss Contingency Accrual Undiscounted Noncurrent
Malpractice Loss Contingency Accrual Undiscounted Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Pediatrix Medical Group in its filing.
Tagged under the XBRL concept us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent.
The official record: Pediatrix Medical Group’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pediatrix Medical Group's malpractice loss contingency accrual undiscounted noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pediatrix Medical Group's malpractice loss contingency accrual undiscounted noncurrent?
- Pediatrix Medical Group (MD) reported malpractice loss contingency accrual undiscounted noncurrent of $236.95M in Q1 2026.
- How has Pediatrix Medical Group's malpractice loss contingency accrual undiscounted noncurrent changed year-over-year?
- Pediatrix Medical Group's malpractice loss contingency accrual undiscounted noncurrent decreased by 4.0% year-over-year, from $246.94M to $236.95M.
- What is the long-term trend for Pediatrix Medical Group's malpractice loss contingency accrual undiscounted noncurrent?
- Over 5 years (2020 to 2025), Pediatrix Medical Group's malpractice loss contingency accrual undiscounted noncurrent has grown at a -2.1% compound annual growth rate (CAGR), from $265.27M to $238.35M.
- What does malpractice loss contingency accrual undiscounted noncurrent mean?
- This metric represents the estimated liability for potential malpractice claims that are expected to be settled beyond the next twelve months, recorded at their undiscounted value. It serves as a provision for legal risks and professional liability exposures inherent in the company's business operations. Tracking this accrual provides insight into the company's long-term legal risk profile and the adequacy of its reserves against potential litigation outcomes.